Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.

Antonio D'Antonio, Simona Losito, Sandro Pignata, Michele Grassi, Francesco Perrone, Antonella De Luca, Rosa Tambaro, Caterina Bianco, William J. Gullick, Gibbes R. Johnson, Vincenzo R. Iaffaioli, David S. Salomon, Nicola Normanno

Research output: Contribution to journalArticlepeer-review


The expression of transforming growth factor alpha (TGFalpha), amphiregulin (AR) and cripto-1 (CR-1) was assessed by immunohistochemistry in 83 specimens (59 primary ovarian tumors and 24 extra-ovarian carcinomas) that were obtained from 68 ovarian carcinoma patients. Within the 59 primary tumors, 54 (92%) expressed immunoreactive TGFalpha, 45 (76%) expressed AR, and 28 (47%) expressed CR-1. The expression of AR and CR-1 mRNAs in the ovarian carcinomas was also demonstrated by RT-PCR analysis. Seventeen extra-ovarian specimens (71%) were found to express CR-1, whereas AR and TGFalpha were expressed respectively in 21 (87%) and 22 (92%) extra-ovarian tissues. In 15 cases for whom both ovarian and extra-ovarian tissues were available, a statistically significant higher expression of CR-1 was found in extra-ovarian specimens. A statistically significant correlation was found between AR expression in the ovarian carcinomas and both low grade and low proliferative activity. Finally, expression of TGFalpha was predictive of longer progression-free survival. These data strongly suggest that the EGF-related peptides might be involved in the pathogenesis and outcome of human ovarian cancer.

Original languageEnglish
Pages (from-to)941-948
Number of pages8
JournalInternational Journal of Oncology
Issue number5
Publication statusPublished - Nov 2002

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.'. Together they form a unique fingerprint.

Cite this